Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;7(2):e00528.
doi: 10.1002/mgg3.528. Epub 2018 Dec 16.

Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases

Wei Liu  1 , Songyun Ouyang  2 , Zhigang Zhou  3 , Meng Wang  3 , Tingting Wang  4 , Yu Qi  5 , Chunling Zhao  2 , Kuisheng Chen  6 , Liping Dai  2   7
Affiliations

Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases

Wei Liu et al. Mol Genet Genomic Med. 2019 Feb.

Abstract

Background: Lung adenocarcinoma (LUAD) accounts for approximately 40% of all lung cancer patients. There is an urgent need to understand the mechanisms of cancer progression in LUAD and to identify useful biomarkers to predict prognosis.

Methods: In this study, Oncomine database was used to identify potential genes contributed to cancer progression. Bioinformatics analysis including pathway enrichment and text mining was used to explain the potential roles of identified genes in LUAD. The Cancer Genome Atlas database was used to analyze the association of gene expression with survival result.

Results: Our results indicated that 80 genes were significantly dysregulated in LUAD according to four microarrays covering 356 cases of LUAD and 164 cases of normal lung tissues. Twenty genes were consistently and stably dysregulated by more than twofold. Ten of 20 genes had a relationship with overall survival or disease-free survival in a cohort of 516 LUAD patients, and 19 genes were associated with tumor stage, gender, age, lymph node, or smoking. Low expression of AGER and high expression of CCNB1 were specifically associated with poor survival.

Conclusion: Our findings implicate AGER and CCNB1 might be potential biomarkers for diagnosis and prognosis targets for LUAD.

Keywords: biomarker; lung adenocarcinoma; microarray; prognosis.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
The 80 genes significantly dysregulated in lung adenocarcinoma (LUAD) according to four independent microarrays retrieved from the Oncomine database. (a) The top 40 genes upregulated in microarrays. (b) The top 40 genes downregulated in microarrays. The four microarrays cover a total of 356 cases of LUAD and 164 cases of normal lung tissues. The rank for a gene is the median rank for the gene across each of the analysis. The p value given for a gene is for the median‐ranked analysis. Genes with red and blue box were significant and consistent overexpression and underexpression in the four studies
Figure 2
Figure 2
Association of the genes with LUAD characteristics was determined by text mining using Coremine Medical and probabilistic scoring (p < 0.05)
Figure 3
Figure 3
Association of genes with OS or DFS, analyzed by Kaplan–Meier survival plots. (a–j) Association of ten genes (AGER, CCNB1, CENPU, CLIL5, COL11A1, FAM107A, FAM189A2, GOLM1, SLIT3, and TMEM106B) with OS. (k–q) Association of seven genes (AGER, CCNB1, CENPU, CLIL5, FAM189A2, GOLM1, and TMEM106B) with DFS. Expression levels of a gene were dichotomized into high expression (green line) and low expression (blue line) using the median as a threshold. DFS: disease‐free survival; OS: overall survival
See this image and copyright information in PMC

References

    1. Allemani, C. , Weir, H. K. , Carreira, H. , Harewood, R. , Spika, D. , Wang, X. S. , … CONCORD Working Group (2015). Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25,676,887 patients from 279 population‐based registries in 67 countries (CONCORD‐2). Lancet, 385, 977–1010. - PMC - PubMed
    1. Androic, I. , Krämer, A. , Yan, R. , Rödel, F. , Gätje, R. , Kaufmann, M. , … Yuan, J. (2008). Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer, 8, 391 10.1186/1471-2407-8-391 - DOI - PMC - PubMed
    1. Armstrong, S. A. , Kung, A. L. , Mabon, M. E. , Silverman, L. B. , Stam, R. W. , Den Boer, M. L. , … Korsmeyer, S. J. (2003). Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell, 3, 173–183. 10.1016/S1535-6108(03)00003-5 - DOI - PubMed
    1. Barrett, T. , Wilhite, S. E. , Ledoux, P. , Evangelista, C. , Kim, I. F. , Tomashevsky, M. , … Soboleva, A. (2013). NCBI GEO: Archive for functional genomics data sets–update. Nucleic Acids Research, 41, D991–D995. - PMC - PubMed
    1. Bender, E. (2014). Epidemiology: The dominant malignancy. Nature, 513, S2–S3. 10.1038/513S2a - DOI - PubMed

Publication types

MeSH terms